Urath Suresh, MD
Nephrology · Knoxville, TNNPI 1629061874
Payments from drug & device makers
Across 609 payments — averaging $179.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$98K
- Amgen$2K
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$1K
- Vifor Pharma, Inc.$914
- Otsuka America Pharmaceutical, Inc.$662
- plus $5K from 28 others
What the payments were for
- Food & beverage$10,87495%
- Education$5815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 32 | $97,671 |
| Amgen(2 entities) | 98 | $1,968 |
| AstraZeneca(2 entities) | 84 | $1,575 |
| Mallinckrodt Hospital Products Inc. | 48 | $1,125 |
| Vifor Pharma, Inc. | 42 | $914 |
| Otsuka America Pharmaceutical, Inc. | 32 | $662 |
| Bayer | 35 | $558 |
| Aurinia Pharma U.S., Inc. | 27 | $556 |
| Akebia Therapeutics Inc | 24 | $466 |
| Fresenius USA Marketing, Inc. | 27 | $452 |
| Calliditas Therapeutics US Inc. | 18 | $448 |
| Travere Therapeutics, Inc. | 26 | $417 |
| Mallinckrodt Enterprises LLC | 11 | $355 |
| OPKO Pharmaceuticals, LLC | 21 | $309 |
| Novartis | 16 | $298 |
| Daiichi Sankyo Inc. | 12 | $252 |
| Sanofi | 6 | $157 |
| Shire North American Group Inc | 9 | $143 |
| GSK | 5 | $98 |
| Alnylam Pharmaceuticals Inc. | 4 | $93 |
| ANI Pharmaceuticals, Inc. | 4 | $90 |
| Kyowa Kirin, Inc. | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Lilly USA, LLC | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| Baxter Healthcare | 2 | $45 |
| Lundbeck LLC | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $37 |
| Portola Pharmaceuticals, LLC | 2 | $36 |
| Ardelyx, Inc. | 2 | $33 |
| AbbVie | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,126 in reported general payments places this provider in the 90th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 339 | $299,391 |
| RayaldeeCalcifediol | 107 | $176,919 |
| KerendiaFinerenone | 94 | $95,454 |
| ProsolParenteral Amino Acid 20% No.1 | 141 | $40,075 |
| VelphoroSucroferric Oxyhydroxide | 18 | $39,884 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $37,882 |
| AuryxiaFerric Citrate | 25 | $33,493 |
| JardianceEmpagliflozin | 18 | $20,782 |
| Clonidine | 88 | $13,159 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $11,257 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,411 |
| Cyclosporine | 11 | $6,535 |
| RetacritEpoetin Alfa-Epbx | 15 | $5,346 |
| Sevelamer Carbonate | 30 | $4,861 |
| Calcium Acetate | 87 | $4,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,575 | $310,648356 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $309 | $176,919107 claims |
| BayerKerendia | $558 | $95,45494 claims |
| Fresenius USA Marketing, Inc.Velphoro | $452 | $39,88418 claims |
| Akebia Therapeutics IncAuryxia | $466 | $33,49325 claims |
| Boehringer IngelheimJardiance | $15 | $20,78218 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $90 | $55719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Knoxville
- Kendra HendonKnoxville$1.1M
- Ross NesbitKnoxville$452K
- Gerald BorrelliKnoxville$190K
- Denise RiversKnoxville$154K
- Jimmy GentryKnoxville$38K
- Erik WendlandKnoxville$34K
- Ritu KhannaKnoxville$12K
- Claude GalphinChattanooga$2M
- Wael HusseinMemphis$912K
- Anna BurgnerNashville$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.